Cellular Classification of Breast Cancer
The following is a list of breast cancer histologic classifications.[1] Infiltrating or invasive ductal cancer is the most common breast cancer histologic type and comprises 70% to 80% of all cases.
- Carcinoma, NOS (not otherwise specified).
- Ductal.
- Intraductal (in situ).
- Invasive with predominant intraductal component.
- Invasive, NOS.
- Comedo.
- Inflammatory.
- Medullary with lymphocytic infiltrate.
- Mucinous (colloid).
- Papillary.
- Scirrhous.
- Tubular.
- Other.
- Lobular.
- In situ.
- Invasive with predominant in situ component.
- Invasive.[2]
- Nipple.
- Paget disease, NOS.
- Paget disease with intraductal carcinoma.
- Paget disease with invasive ductal carcinoma.
- Other.
- Undifferentiated carcinoma.
The following are tumor subtypes that occur in the breast but are not considered to be typical breast cancers:
Stages of Central Nervous System Atypical Teratoid / Rhabdoid Tumor
There is no standard staging system for central nervous system atypical teratoid/rhabdoid tumor. The extent or spread of cancer is usually described as stages. There is no standard staging system for central nervous systematypical teratoid/rhabdoid tumor. This tumor is classified as newly diagnosed or recurrent. Treatment depends on how much cancer remains after surgery and the age of the child. Results from the following procedures are used to plan treatment: MRI (magnetic resonance...
Read the Stages of Central Nervous System Atypical Teratoid / Rhabdoid Tumor article > >
References:
- Breast. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 347-76.
- Yeatman TJ, Cantor AB, Smith TJ, et al.: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg 222 (4): 549-59; discussion 559-61, 1995.
- Chaney AW, Pollack A, McNeese MD, et al.: Primary treatment of cystosarcoma phyllodes of the breast. Cancer 89 (7): 1502-11, 2000.
- Carter BA, Page DL: Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Hum Pathol 35 (9): 1051-2, 2004.
WebMD Public Information from the National Cancer Institute

